News Report · Rheumatoid Arthritis

FDA Approves First Biosimilar to Actemra: Tofidence for Rheumatoid Arthritis

June 14, 2026

Clinical Perspective

Tofidence will be used by rheumatologists treating patients with rheumatoid arthritis, particularly those who may benefit from a more affordable biosimilar option. The approval supports the use of Tofidence as a safe and effective alternative to Actemra, with no clinically meaningful differences in efficacy. What additional data will emerge regarding long-term safety and efficacy in diverse patient populations?

Editorial Team · Rheumatoid Arthritis

The FDA approved Tofidence (tocilizumab-bavi) as a biosimilar to Actemra (tocilizumab) for the treatment of rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in patients aged 2 and older, and systemic juvenile idiopathic arthritis in patients aged 2 and older. This approval is based on a comprehensive review demonstrating that Tofidence is highly similar to Actemra, with no clinically meaningful differences in safety or efficacy ^[7].

Clinical Context

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, and potential joint damage. The condition affects millions of people in the United States, with an estimated prevalence of 1.3 million adults. Current treatment options include disease-modifying antirheumatic drugs (DMARDs), biologics, and JAK inhibitors, which aim to control inflammation and prevent joint damage. However, the high cost of biologic therapies has limited access for many patients, creating a significant gap in treatment options. The introduction of biosimilars like Tofidence aims to enhance accessibility to effective treatments for RA, providing a more affordable alternative to existing biologics ^[1]^[2].

Key Findings

The FDA approval of Tofidence is based on a comprehensive review of its similarity to Actemra, demonstrating that it has no clinically meaningful differences in safety or efficacy ^[7].
Tofidence is indicated for the treatment of rheumatoid arthritis in adults and for polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 and older ^[7].
The approval is expected to increase access to effective treatment options for patients with RA, particularly in low- and middle-income countries where healthcare budgets are constrained ^[1].
The biosimilar is administered via intravenous infusion, similar to its reference product ^[7].
The introduction of Tofidence is part of a broader trend towards the use of biosimilars to improve patient access to essential biologic therapies ^[1].
Clinicians should consult the prescribing information for Tofidence for full dosing guidance and safety information ^[7].

Safety & Tolerability

Upper respiratory tract infections reported with Tofidence — exact frequency not available in public source summary ^[7].
Hypertension reported — exact frequency not available in public source summary ^[7].
Headache reported ^[7].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception ^[7].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for Tofidence (tocilizumab-bavi) ^[7].

Study Design

The approval of Tofidence was based on a comprehensive analysis of data demonstrating its similarity to Actemra. This included pharmacokinetic studies in healthy subjects and clinical studies in patients with rheumatoid arthritis inadequately controlled by methotrexate. The primary endpoint was to demonstrate similarity in efficacy, safety, and immunogenicity endpoints. The studies followed rigorous FDA guidelines for biosimilar approval, ensuring that Tofidence meets the necessary standards for quality, safety, and efficacy ^[7].

FAQ

What is Tofidence approved for?

Tofidence is approved for the treatment of rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in patients aged 2 and older, and systemic juvenile idiopathic arthritis in patients aged 2 and older. This approval is based on a comprehensive review demonstrating its similarity to Actemra.

How does Tofidence work?

Tofidence is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system, thereby reducing inflammation and joint damage associated with rheumatoid arthritis.

What is the recommended dose of Tofidence?

Full dosing guidance is available in the prescribing information for Tofidence (tocilizumab-bavi).

What are the most common side effects of Tofidence?

Common side effects include upper respiratory tract infections, hypertension, and headache. Patients should be monitored for these and other potential adverse effects during treatment.

FDA Approves First Biosimilar to Actemra: Tofidence for Rheumatoid Arthritis

FDA Approves First Biosimilar to Actemra: Tofidence for Rheumatoid Arthritis

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Rheumatoid Arthritis in your inbox.

Verified HCP Portal